secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allogene Therapeutics, Inc. (ALLO)
CIK:        0001737287
Form:       8-K
Filed at:   2025-08-01T23:59:59+00:00
Accession:  0001193125-25-171091
Event type: other_material
Sentiment:  negative
Materiality: 0.90
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Allogene drops ALLO-647 after Grade 5 death; pivots to Dagger platform
----------------------------------------------------------------------

- Grade 5 hepatic failure from adenovirus attributed to ALLO-647; FC+ALLO-647 arm closed in ALPHA3 study.
- ALLO-647 removed from all ongoing and pipeline programs; no trial includes it.
- ALPHA3 proceeds as randomized trial of cema-cel with standard FC vs observation.
- Futility analysis on MRD conversion expected in first half 2026.
- Over 50 clinical sites activated; next-gen AlloCAR T uses Dagger Platform to reduce lymphodepletion.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737287/000119312525171091/0001193125-25-171091-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737287/000119312525171091/d75167d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-171091

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer